INDIA – Molbio Diagnostics has signed an agreement with Testi Technologies, a Finnish innovation leader, to jointly manufacture a flagship product PROMILLESS, a saliva-based diagnostics test to measure body alcohol content.

In a joint statement, Tommi Vaskivuo, Chairman of Testi Technologies Ltd. said: “This partnership unites Testi Technologies’ innovation in enzymatic test technology with Molbio Diagnostics’ technological strength, production capabilities and extensive global network.”

With the launch of the PROMILLESS alcohol content test, Molbio Diagnostics has expanded its extensive diagnostic product portfolio with the aim of providing accessible healthcare solutions.

Molbio Diagnostics offers a global first platform that can perform Molecular Diagnostics for infectious diseases at the point-of-care – Truelab Real Time Quantitative micro–PCR System.

The company’s system brings PCR technology right to the point-of-care, at all laboratory and non-laboratory settings, primary centres, in the field, near patient, essentially at all levels of healthcare.

In partnership with VTT (Technical Research Centre of Finland), Molbio Diagnostics and Testi Technologies have pioneered a smart enzymatic ink, propelling their flagship product to nearly a million sales.

After earning Class I medical device registration in the European Union, the PROMILLESS alcohol content test is now available over the counter.

The patented device has its own set of unique characteristics to help individuals enjoy life responsibly and with reliable information they can make the right choices.

Together, we are set to revolutionize healthcare diagnostics, blending our strengths to offer advanced, accessible solutions,” outlined Tommi Vaskivuo.

The self-test alcohol strip recognizes alcohol content from saliva and determines if the alcohol content is above or below the indicated threshold level.

Under the newly forged agreement, Molbio Diagnostics will have the rights to commercialize, market, and sell PROMILLESS under its own brand name globally.

The launch of this CE-approved class 1 device comes as alcohol consumption contributes to 3 million deaths each year globally as well as to the disabilities and poor health of millions of people.

Efficient diagnostic solutions

According to the World Health Organization, the harmful use of alcohol is accountable for 7.1% and 2.2% of the global burden of disease for males and females respectively.

A variety of factors, that affect the levels and patterns of alcohol consumption and the magnitude of alcohol-related problems in populations, have been identified at individual and societal levels.

The United Nations agency confirmed that health, safety, and socioeconomic problems attributable to alcohol can be reduced when governments formulate and implement appropriate policies.

WHO emphasizes the creation, compilation, and dissemination of scientific information on alcohol use and dependence, and related health and social consequences.

Through the new partnership, Molbio Diagnostics and Testi Technologies agreed to make self-tests available over the counter for use by consumers and law enforcement.

The partnership paves the way for a scientifically proven method to monitor an individual’s alcohol use thereby delivering cost-effective interventions for harmful use of alcohol.

For his part, Tommi Vaskivuo reflected: “This collaboration is a powerful step towards making a significant impact on global health.”

Notably, Testi Technologies has created a revolutionary platform to enable for the first time rapid enzymatic testing using intelligent paper technology coupled with innovative biochemistry.

Located in Helsinki, Southern Finland, Testi Technologies specializes in developing groundbreaking saliva-based enzymatic tests.

It is worth highlighting that Testi Technologies’ proprietary technology enables the embedding of enzymatic components into printable tests.

This opens up a new avenue of unique biomedical testing solutions that enable accurate, reliable, and convenient testing of a large variety of biochemical tests in saliva.

In his address, Sriram Natarajan, Chief Executive Officer of Molbio Diagnostics Pvt. Ltd, expressed his delight to be a joint development, manufacturing, and go-to market partner of Testi Technologies.

Testi Technologies develops non-invasive enzymatic testing technology that enables simple, rapid, and accurate detection of analytes in saliva, by just touching the test stick to the tongue,” said Sriram Natarajan.

New product launches

Broadening its scope, Testi Technologies is venturing into both human and pet healthcare markets with a forthcoming saliva-based glucose test.

This expansion is part of a well-structured product roadmap, underlining Testi Technologies’ commitment to revolutionizing healthcare diagnostics through a series of innovative enzymatic medical tests.

In addition to the PROMILLESS alcohol content test, Molbio Diagnostics inked a strategic collaboration with Testi Technologies in the areas of technical development, manufacturing, marketing, sales, and promotion of an array of diagnostic products.

Commenting on this move, Sriram Natarajan underscored: “The current test for alcohol, the upcoming test for glucose, and many more human and veterinary tests in the pipeline will prove to be revolutionary.”

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.